CJC-1295 NO DAC + IPAMORELIN
$129.00
AUDBuy CJC-1295 NO DAC + IPAMORELIN Australia
A dual-peptide research blend combining GHRH and ghrelin-receptor signalling pathways for investigating coordinated neuroendocrine and pituitary communication.
In stock
Out of Stock
RESEARCH USE ONLY
AMINOSPX products are supplied exclusively for legitimate laboratory, analytical, scientific and in vitro research purposes and are not intended for human or animal consumption.
Overview
CJC-1295 No DAC + Ipamorelin is a synthetic research peptide combination that brings together two complementary neuroendocrine signalling pathways within a single experimental model. CJC-1295 No DAC (Modified GRF 1–29) is a short-acting GHRH analogue, while Ipamorelin is a selective pentapeptide growth hormone secretagogue that interacts with the ghrelin receptor (GHSR-1a). Together, these distinct peptide systems provide researchers with an integrated model for exploring receptor cross-talk, coordinated pituitary communication and interactions between GHRH and ghrelin-receptor signalling.
For legitimate laboratory, analytical, scientific and in vitro research purposes only.
Not intended for human consumption, medical use, therapeutic application, diagnostic use, veterinary use, cosmetic use or food use.
Molecular Profile
A dual-peptide research blend combining GHRH and ghrelin-receptor signalling pathways for investigating coordinated neuroendocrine and pituitary communication.
Total Blend Strength: 10mg
-
CJC-1295 No DAC 5mg
-
Ipamorelin 5mg
Research Applications
Modified GHRH Analogue and Selective Growth Hormone Secretagogue Peptide Combination is studied in laboratory and in-vitro research across several areas of scientific interest, including:
GHRH/GHSR Signalling Research
Used as a combined model for investigating GHRH and ghrelin-receptor signalling pathways.
GH Pulsatility Research
Used to investigate mechanisms associated with pulsatile GH signalling.
GH/IGF-1 Axis Research
Studied for downstream signalling associated with experimental modulation of GH pathways
Receptor Pathway Interaction
Provides a model for investigating interactions between GHRH and GHSR signalling.
Research Disclaimer
Information provided on this page is supplied solely for laboratory, analytical, scientific and in vitro research purposes. Products are not intended for human or veterinary use, and the information provided does not constitute medical, pharmaceutical, healthcare or other professional advice.
Nothing contained on this website should be interpreted as a recommendation regarding the diagnosis, treatment, prevention or management of any disease, condition or health outcome.
Researchers are responsible for determining the suitability of products for their intended laboratory applications and for ensuring compliance with all applicable laws, regulations and institutional requirements.
Storage & Handling
Appropriate storage and laboratory handling help maintain product integrity and research consistency.
Storage Recommendations
- Store the lyophilised compound sealed and dry below 25°C.
- Once reconstituted, store at 2–8°C in accordance with the applicable laboratory research protocol.
- Minimise repeated freeze-thaw cycles.
- Protect from heat, moisture and direct light.
Handling Recommendations
- Use appropriate laboratory personal protective equipment (PPE).
- Follow recognised laboratory procedures appropriate to the intended research application.
- Avoid contact with eyes or skin, and avoid inhalation or ingestion.
- Maintain appropriate product identification and laboratory documentation.
- Dispose of unused material according to institutional procedures and applicable regulations.
Certificate of Analysis (COA)
Important Information
Certificates of Analysis are obtained through independent third-party analytical laboratories and provided for research and informational purposes only.
Compounds tested are intended for research use only and are not approved for human or veterinary use, diagnostic, therapeutic or clinical applications.
Results should be interpreted by qualified professionals within the scope of the intended research and should not be considered a guarantee of suitability for any particular application.
Frequently Asked Questions
What is CJC-1295 No DAC + Ipamorelin?
CJC-1295 No DAC + Ipamorelin combines two research peptides that interact with distinct but complementary signalling systems. CJC-1295 No DAC targets the GHRH receptor pathway, while Ipamorelin interacts with the ghrelin receptor, creating an experimental model for studying how these pathways communicate.
Which peptides are included in this combination?
The combination contains 5 mg of CJC-1295 No DAC (Modified GRF 1–29) and 5 mg of Ipamorelin, providing a total labelled blend strength of 10 mg.
What research areas is this peptide combination associated with?
The combination provides researchers with a model for examining interactions between GHRH and ghrelin-receptor signalling, including receptor cross-talk, pulsatile signalling and coordinated pituitary communication. This allows the relationship between the two signalling pathways to be investigated within the same experimental model.
How should CJC-1295 No DAC + Ipamorelin be stored?
Store the lyophilised material in a sealed, dry environment below 25°C. Where laboratory reconstitution is undertaken, store reconstituted material at 2–8°C. Avoid freeze–thaw cycles to help preserve product integrity.
Customer Reviews
Be the first to leave a review
Share your experience with this product and help other researchers make informed decisions.
Share your experience with this product.
